全球人类胰岛素市场规模、份额、成长分析，按类型、应用、分销管道 - 产业预测，2024-2031 年

2022年全球人类胰岛素市场规模为190.5亿美元，从2023年的193.7亿美元成长到2031年的221.7亿美元，预计在预测期间（2024-2031年）复合年增长率为1.7%。美元。

人类胰岛素的全球市场受到糖尿病盛行率上升的推动，并在全球糖尿病管理中发挥重要作用。该部门致力于透过生产人类胰岛素产品并将其分销给世界各地的医疗机构、药房和患者来满足对胰岛素不断增长的需求。根据国际糖尿病联盟预测，到 2045 年，诊断出糖尿病的人数将达到 7 亿，这正在推动市场扩张。重组 DNA 技术等技术进步正在创造更安全、更有效的胰岛素製剂，推动其采用和市场成长。儘管努力改善可近性，胰岛素的高成本仍然是一个主要障碍，特别是在低收入地区，受到製造成本上升和监管复杂性的阻碍。从传统胰岛素转向功效优越的类似胰岛素的转变已成为普遍趋势，进一步推动了市场成长。此外，对提供便利性和准确性的胰岛素输送设备的需求不断增长，而连网型设备和人工智慧等新技术正在推动其采用。

目录

执行摘要

• 市场概况
• 繁荣与衰落

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模估算
• 市场危机与限制

母市场分析

• 市场概况
• 市场规模
• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务

主要市场考察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• Start-Ups分析
• 原料分析
• 创新矩阵
• 研发线产品分析
• 总体经济指标
• 主要投资分析
• 关键成功因素
• 竞争程度

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 监管环境
• 波特的分析
• 对未来中断的特殊考虑

全球人类胰岛素市场：按类型

• 市场概况
• 常规人类胰岛素和胰岛素类似物

人类胰岛素的全球市场：依应用分类

• 市场概况
• 1型糖尿病
• 2型糖尿病
• 妊娠糖尿病

全球人胰岛素市场：按分销管道划分

• 市场概况
• 医院药房
• 零售药房
• 网路药房
• 糖尿病诊所

全球人类胰岛素市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2021年）
• 主要市场参与者所采取的策略
• 关键成功策略
• 近期市集活动
• 主要企业市场占有率（2021年）

主要企业简介

• 诺和诺德（丹麦）
• 礼来公司（美国）
• 赛诺菲（法国）
• 默克公司（美国）
• 辉瑞公司（美国）
• 阿斯特捷利康（英国）
• 强生公司（美国）
• Biocon 有限公司（印度）
• Ypsomed AG（瑞士）
• 沃克哈特有限公司（印度）
• Julphar（阿拉伯联合大公国）
• 甘李药业（中国）
• Bioton SA（波兰）
• 阿多西亚（法国）
• Torrent 製药有限公司（印度）
• 柏林化学股份公司（德国）
• SemBioSys Genetics Inc.（加拿大）
• Biodel 公司（美国）
• 东宝企业集团股份有限公司 (中国)
• 通化东宝药业有限公司 (中国)

Global Human Insulin Market size was valued at USD 19.05 Billion in 2022 and is poised to grow from USD 19.37 Billion in 2023 to USD 22.17 Billion by 2031, at a CAGR of 1.7% during the forecast period (2024-2031).

The Global Human Insulin Market serves as a vital component in managing diabetes worldwide, propelled by the escalating prevalence of the condition. This sector endeavors to meet the mounting demand for insulin by producing and distributing human insulin products to healthcare facilities, pharmacies, and patients globally. The exponential increase in diabetes diagnoses, projected to reach 700 million by 2045 according to the International Diabetes Federation, fuels the market's expansion. Technological advancements like recombinant DNA technology have yielded safer and more effective insulin products, fostering their adoption and market growth. Despite efforts to enhance accessibility, the high cost of insulin persists as a significant barrier, especially in low-income regions, hindered by elevated production costs and regulatory complexities. Transitioning from traditional to analog insulin, with its superior efficacy, has become a prevalent trend, further propelling market growth. Additionally, there's a rising demand for insulin delivery devices, offering convenience and accuracy, with emerging technologies like connected devices and artificial intelligence driving their adoption.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Insulin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Insulin Market Segmental Analysis

Global Human Insulin Market is segmented on the basis of type, application, distribution channel, and region. By type, the market is segmented into traditional human insulin and analog insulin. By application, the market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and diabetes clinics. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Human Insulin Market

The increasing incidence of diabetes globally serves as a major catalyst for the expansion of the worldwide human insulin market. According to the International Diabetes Federation, approximately 463 million adults had diabetes in 2019, a figure anticipated to climb to 700 million by 2045. This burgeoning population of individuals with diabetes creates a greater need for insulin, propelling market growth. For instance, nations such as China and India have experienced a surge in diabetes cases attributable to shifting lifestyles and dietary patterns, consequently driving up the demand for human insulin.

Restraints in the Global Human Insulin Market

Regulatory barriers and patent exclusivity pose significant obstacles in the human insulin market, constraining competition and market entry. Securing regulatory approvals for novel insulin products or biosimilars demands extensive testing and adherence to strict regulations. Furthermore, the exclusivity granted to specific insulin formulations restricts the proliferation of generic alternatives, thereby limiting patient choices and hindering market expansion. Notably, the dominance of certain long-acting insulin analogs under patent protection further impedes the introduction of biosimilar counterparts into the market.

Market Trends of the Global Human Insulin Market

A discernible shift is observed in the market as it moves away from conventional human insulin towards analog insulin, which provides benefits like quicker onset, shorter action duration, and enhanced glycemic control. Healthcare professionals and individuals with diabetes are progressively embracing analog insulin to attain superior management of the condition. Notably, long-acting analog insulin such as insulin glargine (Lantus) and insulin detemir (Levemir) have witnessed substantial market growth owing to their improved pharmacokinetic profiles.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Human Insulin Market by Type

• Market Overview
• Traditional human insulin and analog insulin

Global Human Insulin Market by Application

• Market Overview
• Type 1 diabetes
• type 2 diabetes
• and gestational diabetes

Global Human Insulin Market by Distribution channel

• Market Overview
• Hospital pharmacies
• retail pharmacies
• online pharmacies
• and diabetes clinics

Global Human Insulin Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Julphar (United Arab Emirates)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gan & Lee Pharmaceuticals (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioton S.A. (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adocia (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Berlin-Chemie AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SemBioSys Genetics Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biodel Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dongbao Enterprise Group Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonghua Dongbao Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments